ARCUTIS BIOTHERAPEUTICS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $111.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2025-05-06
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $111.00K, a 14.43% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-12-31 was $107.00K, a 13.83% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-09-30 was $103.00K, a 13.19% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-06-30 was $101.00K, a 14.77% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $408.00K, a 13.33% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $360.00K, a 12.85% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $319.00K, a 3.24% increase from fiscal 2021.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $309.00K, a 7.21% decline from fiscal 2020.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2025-03-31 | $111.00K 10-Q · filed 2025-05-06 | $218.00K derived: sum of 2 quarters · filed 2025-05-06 | $321.00K derived: sum of 3 quarters · filed 2025-05-06 | $422.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | $107.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $210.00K derived: sum of 2 quarters · filed 2025-02-25 | $311.00K derived: sum of 3 quarters · filed 2025-02-25 | $408.00K 10-K · filed 2025-02-25 |
| 2024-09-30 | $103.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $204.00K derived: sum of 2 quarters · filed 2024-11-06 | $301.00K 10-Q · filed 2024-11-06 | $395.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-06-30 | $101.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $198.00K 10-Q · filed 2024-08-14 | $292.00K derived: sum of 3 quarters · filed 2025-05-06 | $383.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-03-31 | $97.00K 10-Q · filed 2025-05-06 | $191.00K derived: sum of 2 quarters · filed 2025-05-06 | $282.00K derived: sum of 3 quarters · filed 2025-05-06 | $370.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $94.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $185.00K derived: sum of 2 quarters · filed 2025-02-25 | $273.00K derived: sum of 3 quarters · filed 2025-02-25 | $360.00K 10-K · filed 2025-02-25 |
| 2023-09-30 | $91.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $179.00K derived: sum of 2 quarters · filed 2024-11-06 | $266.00K 10-Q · filed 2024-11-06 | $348.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $88.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $175.00K 10-Q · filed 2024-08-14 | $257.00K derived: sum of 3 quarters · filed 2025-02-25 | $336.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $87.00K 10-Q · filed 2024-05-14 | $169.00K derived: sum of 2 quarters · filed 2025-02-25 | $248.00K derived: sum of 3 quarters · filed 2025-02-25 | $327.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $161.00K derived: sum of 2 quarters · filed 2025-02-25 | $240.00K derived: sum of 3 quarters · filed 2025-02-25 | $319.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | $79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $158.00K derived: sum of 2 quarters · filed 2023-11-03 | $237.00K 10-Q · filed 2023-11-03 | $312.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $79.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $158.00K 10-Q · filed 2023-08-08 | $233.00K derived: sum of 3 quarters · filed 2024-02-27 | $309.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $79.00K 10-Q · filed 2023-05-09 | $154.00K derived: sum of 2 quarters · filed 2024-02-27 | $230.00K derived: sum of 3 quarters · filed 2024-02-27 | $308.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $151.00K derived: sum of 2 quarters · filed 2024-02-27 | $229.00K derived: sum of 3 quarters · filed 2024-02-27 | $309.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | $76.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $154.00K derived: sum of 2 quarters · filed 2022-11-08 | $234.00K 10-Q · filed 2022-11-08 | $365.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $78.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $158.00K 10-Q · filed 2022-08-04 | $289.00K derived: sum of 3 quarters · filed 2023-02-28 | $426.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $80.00K 10-Q · filed 2022-05-05 | $211.00K derived: sum of 2 quarters · filed 2023-02-28 | $348.00K derived: sum of 3 quarters · filed 2023-02-28 | $375.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $131.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $268.00K derived: sum of 2 quarters · filed 2023-02-28 | $295.00K derived: sum of 3 quarters · filed 2023-02-28 | $333.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | $137.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $164.00K derived: sum of 2 quarters · filed 2021-11-04 | $202.00K 10-Q · filed 2021-11-04 | $238.00K derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $65.00K 10-Q · filed 2021-08-05 | $101.00K derived: sum of 3 quarters · filed 2022-02-22 | |
| 2020-03-31 | $38.00K 10-Q · filed 2021-05-06 | $74.00K derived: sum of 2 quarters · filed 2022-02-22 | ||
| 2019-12-31 | $36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $127.00K 10-K · filed 2022-02-22 | ||
| 2019-09-30 | $91.00K 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |